首页> 外文期刊>Therapeutics and Clinical Risk Management >Role of statins in preventing cardiac surgery-associated acute kidney injury: an updated meta-analysis of randomized controlled trials
【24h】

Role of statins in preventing cardiac surgery-associated acute kidney injury: an updated meta-analysis of randomized controlled trials

机译:他汀类药物在预防与心脏手术有关的急性肾脏损伤中的作用:随机对照试验的最新荟萃分析

获取原文
           

摘要

Background: The prevention of cardiac surgery-associated acute kidney injury (CSA-AKI) by statins remains controversial. Therefore, the present meta-analysis including randomized controlled trials (RCTs) was performed to assess the effect of perioperative statin on CSA-AKI. Methods: Two reviewers independently searched for RCTs about perioperative statin for prevention of CSA-AKI. The primary endpoint was CSA-AKI. Relative risk was calculated between statin and placebo for preventing CSA-AKI using the random-effect model or fixed-effect model according to different heterogeneity. Results: Eight RCTs met inclusion criteria, including five studies with atorvastatin, two with rosuvastatin, and one with simvastatin. There were 1,603 patients receiving statin treatment and 1,601 with placebo. Perioperative statin therapy did not reduce the incidence of CSA-AKI (relative risk =1.17, 95% CI: 0.98–1.39, p =0.076). Furthermore, perioperative statin increased the risk of CSA-AKI in the subgroup analysis with clear definition of CSA-AKI and those with JADAD score >3. Perioperative rosuvastatin produced slightly significantly higher risk of AKI than atorvastatin therapy ( p =0.070). Statin intervention both pre and post surgery slightly increased the risk of CSA-AKI versus preoperative statin therapy alone ( p =0.040). Conclusions: Perioperative statin therapy might increase the risk of CSA-AKI after cardiac surgery.
机译:背景:他汀类药物预防与心脏手术相关的急性肾损伤(CSA-AKI)仍存在争议。因此,进行了包括随机对照试验(RCT)在内的本荟萃分析,以评估围手术期他汀类药物对CSA-AKI的影响。方法:两名评价员独立搜索围手术期他汀类药物预防CSA-AKI的RCT。主要终点是CSA-AKI。根据不同的异质性,使用随机效应模型或固定效应模型计算了他汀类药物和安慰剂之间预防CSA-AKI的相对风险。结果:八项RCT符合纳入标准,包括五项阿托伐他汀研究,两项瑞舒伐他汀研究和一项辛伐他汀研究。有1,603例接受他汀类药物治疗的患者和1,601例接受安慰剂治疗的患者。围手术期他汀类药物治疗并未降低CSA-AKI的发生率(相对危险度= 1.17,95%CI:0.98–1.39,p = 0.076)。此外,在亚组分析中,围手术期他汀类药物增加了CSA-AKI的风险,明确定义了CSA-AKI和JADAD评分> 3的患者。与阿托伐他汀治疗相比,围手术期瑞舒伐他汀产生AKI的风险略高(p = 0.070)。与单独使用他汀类药物治疗前相比,他汀类药物在手术前后的干预均稍微增加了CSA-AKI的风险(p = 0.040)。结论:围手术期他汀类药物治疗可能会增加心脏手术后CSA-AKI的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号